<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Shi J</submitter><funding>Chinese Academy of Medical Science Clinical and Translational Medicine Research Foundation</funding><funding>National Natural Science Foundation of China</funding><funding>Emergency Key Program of Guangzhou Laboratory</funding><funding>Capital Health Development Scientific Research Project</funding><pagination>19</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9835228</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>21(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Due to the temporal and spatial heterogeneity of human epidermal growth factor receptor 2 (HER2) expression in breast tumors, immunohistochemistry (IHC) cannot accurately reflect the HER2 status in real time, which may cause misguided treatment decisions. HER2-specific imaging can noninvasively determine HER2 status in primary and metastatic tumors. In this study, HER2 expression in breast cancer patients was determined in vivo by SPECT/CT of &lt;sup>99m&lt;/sup>Tc-HP-Ark2, comparing with PET/CT of &lt;sup>18&lt;/sup>F-FDG lesion by lesion.&lt;h4>Methods&lt;/h4>A novel HER2-targeted peptide probe &lt;sup>99m&lt;/sup>Tc-HP-Ark2 was constructed. Biodistribution and nanoScan SPECT/CT imaging were performed in mice models. The correlation between the quantified tumor uptake and HER2 expression in t</pubmed_abstract><journal>Journal of translational medicine</journal><pubmed_title>Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer &lt;sup>99m&lt;/sup>Tc-HP-Ark2: a pilot study.</pubmed_title><pmcid>PMC9835228</pmcid><funding_grant_id>2018-1-4011</funding_grant_id><funding_grant_id>81927802</funding_grant_id><funding_grant_id>81630045</funding_grant_id><funding_grant_id>92159201</funding_grant_id><funding_grant_id>EKPG21-16</funding_grant_id><funding_grant_id>81971676</funding_grant_id><funding_grant_id>2019XK320032</funding_grant_id><pubmed_authors>Luo Q</pubmed_authors><pubmed_authors>Du S</pubmed_authors><pubmed_authors>Zhu Z</pubmed_authors><pubmed_authors>Wang R</pubmed_authors><pubmed_authors>Wang F</pubmed_authors><pubmed_authors>Gao H</pubmed_authors><pubmed_authors>Shi J</pubmed_authors><pubmed_authors>Zhou Y</pubmed_authors><pubmed_authors>Hou G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer &lt;sup>99m&lt;/sup>Tc-HP-Ark2: a pilot study.</name><description>&lt;h4>Background&lt;/h4>Due to the temporal and spatial heterogeneity of human epidermal growth factor receptor 2 (HER2) expression in breast tumors, immunohistochemistry (IHC) cannot accurately reflect the HER2 status in real time, which may cause misguided treatment decisions. HER2-specific imaging can noninvasively determine HER2 status in primary and metastatic tumors. In this study, HER2 expression in breast cancer patients was determined in vivo by SPECT/CT of &lt;sup>99m&lt;/sup>Tc-HP-Ark2, comparing with PET/CT of &lt;sup>18&lt;/sup>F-FDG lesion by lesion.&lt;h4>Methods&lt;/h4>A novel HER2-targeted peptide probe &lt;sup>99m&lt;/sup>Tc-HP-Ark2 was constructed. Biodistribution and nanoScan SPECT/CT imaging were performed in mice models. The correlation between the quantified tumor uptake and HER2 expression in t</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2026-05-28T06:11:43.086Z</modification><creation>2025-02-19T02:22:02.482Z</creation></dates><accession>S-EPMC9835228</accession><cross_references><pubmed>36631812</pubmed><doi>10.1186/s12967-022-03865-y</doi></cross_references></HashMap>